Experienced in Prothrombin Deficiency

Dr. Raul R. Mena

Burbank, CA
Experienced
in Prothrombin Deficiency
Specialties:Hematology Oncology
OverviewInsuranceLocationsClinical Research

Overview

Raul Mena is a Hematologist Oncology provider in Burbank, California. Dr. Mena and is rated as an Experienced provider by MediFind in the treatment of Prothrombin Deficiency. His top areas of expertise are Lung Cancer, Adult Soft Tissue Sarcoma, Paget Disease of the Breast, Bone Marrow Aspiration, and Endoscopy.

His clinical research consists of co-authoring 3 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Licenses
Internal Medicine in CA
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Humana

Locations

181 S Buena Vista St, 4rth Floor, Burbank, CA 91505
818-840-0921

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 24, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) an dCD30-expressing Peripheral T-cell Lymphoma (PTCL) in Older Patients or Patients With Significant Comorbidities Ineligible for Standard Chemotherapy
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) an dCD30-expressing Peripheral T-cell Lymphoma (PTCL) in Older Patients or Patients With Significant Comorbidities Ineligible for Standard Chemotherapy
Enrollment Status: Completed
Publish Date: June 11, 2024
Intervention Type: Drug
Study Drugs: Brentuximab, Bendamustine, Dacarbazine, Nivolumab
Study Phase: Phase 2
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
Enrollment Status: Completed
Publish Date: November 23, 2022
Intervention Type: Drug, Biological
Study Drugs: Margetuximab, Trastuzumab, Capecitabine, Eribulin, Gemcitabine, Vinorelbine
Study Phase: Phase 3
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
Enrollment Status: Terminated
Publish Date: June 07, 2022
Intervention Type: Drug
Study Phase: Phase 2
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Enrollment Status: Terminated
Publish Date: March 23, 2022
Intervention Type: Drug
Study Drugs: Trilaciclib, Gemcitabine, Carboplatin
Study Phase: Phase 2
View 4 Less Clinical Trials

3 Total Publications

The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma.
The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma.
Journal: British journal of haematology
Published: September 13, 2019
Similar Doctors
Expertise in
61
conditions
Dr. Shahrooz Eshaghian
Hematology Oncology | Hematology | Oncology
Expertise in
61
conditions
Dr. Shahrooz Eshaghian
Hematology Oncology | Hematology | Oncology

Los Angeles Hematology-Oncology Medical Group

2080 Century Park E, Suite 1005, 
Los Angeles, CA 
 (8.4 mi)
310-229-3555
Languages Spoken:
English
Offers Telehealth

Shahrooz Eshaghian is a Hematologist Oncology specialist and a Hematologist in Los Angeles, California. Dr. Eshaghian and is rated as a Distinguished provider by MediFind in the treatment of Prothrombin Deficiency. His top areas of expertise are Multiple Myeloma, Bone Tumor, Deep Vein Thrombosis, Anemia, and Bone Marrow Aspiration.

Expertise in
70
conditions
Dr. Casey L. O'connell
Hematology Oncology | Hematology | Oncology
Expertise in
70
conditions
Dr. Casey L. O'connell
Hematology Oncology | Hematology | Oncology

USC Care Medical Group Inc

1520 San Pablo St, 
Los Angeles, CA 
 (9.8 mi)
800-872-2273
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Casey O'connell is a Hematologist Oncology specialist and a Hematologist in Los Angeles, California. Dr. O'connell and is rated as an Elite provider by MediFind in the treatment of Prothrombin Deficiency. Her top areas of expertise are Polycythemia Vera, Myelodysplastic Syndrome (MDS), Myelofibrosis, Bone Marrow Aspiration, and Splenectomy.

Expertise in
38
conditions
Dr. Howard A. Liebman
Hematology Oncology | Hematology
Expertise in
38
conditions
Dr. Howard A. Liebman
Hematology Oncology | Hematology

USC Care Medical Group Inc

1520 San Pablo St, 
Los Angeles, CA 
 (9.8 mi)
800-872-2273
Languages Spoken:
English
See accepted insurances

Howard Liebman is a Hematologist Oncology specialist and a Hematologist in Los Angeles, California. Dr. Liebman and is rated as an Elite provider by MediFind in the treatment of Prothrombin Deficiency. His top areas of expertise are Immune Thrombocytopenic Purpura (ITP), Adult Immune Thrombocytopenia, Thrombocytopenia, Purpura, and Splenectomy.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile